Original PaperSurvival of patients with oesophageal and gastric cancers in Europe
Introduction
Oesophageal and gastric cancers remain common and serious diseases. Data on survival from these cancers have mostly been provided by specialised hospital units or from clinical trial series, with unavoidable selection bias, particularly with respect to elderly and those with comorbidity. Population-based series recording all cases diagnosed in a well-defined population allow the assessment of the real prognosis of oesophageal and gastric cancers. International comparisons of survival estimates after cancer diagnosis are now possible with the data collected by cancer registries over recent years[1]. These data can address questions of whether survival rates differ between countries and whether they are improving with time. The first EUROCARE study based on combined data from 11 countries provided survival rates for cancer patients diagnosed during the 1978–1985 period. The collaboration across Europe in the EUROCARE study has now been extended to 17 countries. The aim of this study was to review, within the framework of this programme, the prognosis of oesophageal and gastric cancers diagnosed between 1985 and 1989 in different countries with a special interest in intercountry comparison and to determine time trends in survival over the 1978–1989 period.
Section snippets
Patients and methods
This study included oesophageal cancers (ICD-9 150) and gastric cancers (ICD-9 151) registered during the 1978–1989 period in areas covered by cancer registries in 17 European countries. Only primary newly diagnosed malignant invasive tumours were considered. In situ cancers or tumours of uncertain malignancy were excluded as well as lymphomas. Cases known by death certificates only (DCO) or discovered incidentally at autopsy were excluded from the survival analysis. Description of the cancer
Inter-country differences in survival
Overall survival rates were poor. The European weighted survival, calculated from the pool of all cancer registries was 33% at 1 year and 10% at 5 years. Even though survival rates were low, there were important differences between countries in the relative survival rates (Table 2). The highest 1-year relative survival rates (more than 35%) were reported in The Netherlands, France and Switzerland, and the lowest (less than 25%) in Slovakia and Denmark. Five-year relative survival rates were
Discussion
In European countries the prognosis of patients with oesophageal and gastric cancers remains poor. In this study, the 5-year relative European weighted survival for the 1985–1989 period was 10% for oesophageal cancers and 21% for gastric cancer. Hospital series often provide more optimistic data[4]. They are of limited value because of unavoidable selection bias, in particular in case selection and patient’s characteristics[5].
One of the main findings of this study was the extensive variation
Acknowledgements
The EUROCARE study was financed through the BIOMED programme of the European Union and the Fondation de France financed the French part of the study on gastric cancer care.
References (18)
- et al.
Computer program package for relative survival rates
Comp Prog Biomed
(1985) - et al.
The influence of age on resection rates and postoperative mortality in 2773 patients with gastric cancer
Eur J Cancer
(1995) - Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J. Survival of cancer patients in Europe. The...
- Berrino F, Capocaccia R, Estève J, et al. Survival of cancer patients in Europe: The EUROCARE Study, II. IARC...
- Sue-Ling HM, Johnston D, Martin IG et al. Gastric cancer: a curable disease in Britain. Brit Med J 1993, 307,...
Centralised treatment, entry to trials and survival
Int J Cancer
(1994)- Berrino F, Esteve J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. In Berrino...
- et al.
Gastric cancer: a 25-year review
Br J Surg
(1989) - Kosary CL, Ries LAG, Miller BA, Mankey BF, Harras A, Edwards BK. SEER Cancer Statistics review 1973–1992. Bethesda, NIH...
Cited by (0)
- 1
The EUROCARE Working Group for this study is listed in the Appendix A.